- Home
- CELC vs MGRC Comparison
CELC vs MGRC Comparison
Compare CELC & MGRC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CELC | MGRC |
|---|---|---|
| Founded | 2011 | 1979 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Diversified Commercial Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.7B |
| IPO Year | 2017 | 1995 |
Fundamental Metrics
Financial Performance| Metric | CELC | MGRC |
|---|---|---|
| Price | $115.02 | $104.73 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 2 |
| Target Price | $106.63 | ★ $141.50 |
| AVG Volume (30 Days) | ★ 538.8K | 122.7K |
| Earning Date | 01-01-0001 | 05-28-2026 |
| Dividend Yield | N/A | ★ 1.89% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 6.35 |
| Revenue | N/A | ★ $944,235,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $4.81 |
| P/E Ratio | ★ N/A | $16.49 |
| Revenue Growth | N/A | ★ 3.65 |
| 52 Week Low | $7.58 | $94.99 |
| 52 Week High | $120.32 | $128.41 |
Technical Indicators
Market Signals| Indicator | CELC | MGRC |
|---|---|---|
| Relative Strength Index (RSI) | 56.96 | 36.38 |
| Support Level | $97.75 | $101.64 |
| Resistance Level | $114.54 | $118.28 |
| Average True Range (ATR) | 5.27 | 3.81 |
| MACD | 0.32 | -0.84 |
| Stochastic Oscillator | 67.83 | 17.15 |
Price Performance
Historical ComparisonAbout CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
About MGRC McGrath RentCorp
McGrath RentCorp is a rental company. It is comprised of four reportable business segments namely Modular building segment (Mobile Modular); Portable storage container segment (Portable Storage); Electronic test equipment segment (TRS-RenTelco); and its classroom manufacturing business selling modular buildings used as classrooms in California (Enviroplex). The company generates its revenues majorily from the rental of its equipment on operating leases with sales of equipment occurring in the normal course of business.